Moderna's stock soars almost 90% on the stock exchange after the success of a clinical trial against skin cancer.
The pharmaceutical company, together with Merck, which rose by around 8%, have announced that they have obtained positive preliminary results in a clinical trial of a vaccine for melanoma.
Moderna and Merck have announced positive preliminary results from a clinical trial of a melanoma vaccine. The vaccine, which combines a RNA therapy with Merck's existing Keytruda medication, has shown a decrease in disease recurrence and metastasis. Moderna's shares surged nearly 90% to $118 in the New York Stock Exchange, while Merck's shares rose around 8% to $145.
The results showed statistically significant and clinically relevant improvements in survival rates and will be presented at an upcoming medical meeting and shared with regulatory authorities.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
